RxDoctor Payments Data

Natalia Dorland, MD

Neurology · Maple Grove, MNNPI 1114241676

Payments from drug & device makers

$714in general payments, 2019–2025

Across 31 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$129
  • Greenwich Biosciences, Inc.$72
  • Novartis$43
  • Neurelis, Inc.$41
  • Takeda Pharmaceuticals U.S.A., Inc.$38
  • Catalyst Pharmaceuticals, Inc.$35
  • plus $356 from 18 others

What the payments were for

  • Food & beverage$64290%
  • Education$7210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714 in reported general payments places this provider in the 60th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$113,379
Medicare patients
279
Services billed
3,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam46$76,033
AptiomEslicarbazepine Acetate26$68,613
XcopriCenobamate51$68,498
VimpatLacosamide22$57,388
Emgality PenGalcanezumab-Gnlm77$56,635
FycompaPerampanel20$33,702
UbrelvyUbrogepant21$25,630
Nurtec OdtRimegepant Sulfate13$23,443
Lamotrigine OdtLamotrigine25$21,988
Lacosamide129$18,995
Aimovig AutoinjectorErenumab-Aooe23$17,205
Ajovy AutoinjectorFremanezumab-Vfrm22$15,955
Levetiracetam232$15,075
EliquisApixaban19$10,746
Ajovy SyringeFremanezumab-Vfrm13$9,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$32$133,42168 claims
SK Life Science, Inc.Xcopri$28$68,49851 claims
PfizerNurtec Odt, Eliquis$22$34,19032 claims
Eisai Inc.Fycompa$15$33,70220 claims
Upsher-smith Laboratories LLCTopiramate$25$1,649129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 neurology providers in Minnesota.

Other neurology in Maple Grove

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →